Recovery of MERRF Fibroblasts and Cybrids Pathophysiology by Coenzyme Q10

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 446-463

  de la Mata, Mario ^a   Garrido Maraver, Juan ^a   Cotán, David ^a   Cordero, Mario D ^a   Oropesa Ávila, Manuel ^a   Izquierdo, Lourdes Gómez ^b   de Miguel, Manuel ^c   Lorite, Juan Bautista ^d   Infante, Eloy Rivas ^b   Ybot, Patricia ^b   Jackson, Sandra ^e   Sánchez Alcázar, José A ^a  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d Hospital QuirónSalud Sagrado Corazón   (Spain)

^e Neurologie Uniklinikum CG Carus   (Germany)

Author keywords

Coenzyme Q10; MERRF; Mitochondrial disease; Mitophagy

Indexed keywords

BECLIN 1; BETA GALACTOSIDASE; CATHEPSIN D; CYTOCHROME C; MITOCHONDRIAL DNA; MITOCHONDRIAL PROTEIN; REACTIVE OXYGEN METABOLITE; UBIDECARENONE;

ARTICLE; AUTOPHAGOSOME; CELL PROLIFERATION; CONTROLLED STUDY; CYBRID; CYTOPLASM; ELECTRON TRANSPORT; FIBROBLAST; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIPID PEROXIDATION; MERRF SYNDROME; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL RESPIRATION; MITOPHAGY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SUPPLEMENTATION;

CELL LINE; CELLS, CULTURED; FIBROBLASTS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MERRF SYNDROME; MUTATION; UBIQUINONE;

EID: 84859700290     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0103-3     Document Type: Article

References (33)

1. Wallace DC. Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci U S A 1994; 91: 8739-8746.
2. Shoffner JM, Lott MT, Lezza AM, et al. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell 1990; 61: 931-937.
3. Erol I, Alehan F, Horvath R, et al. Demyelinating disease of central and peripheral nervous systems associated with a A8344G mutation in tRNALys. Neuromuscul Disord 2009; 19: 275-278.
4. Wallace DC, Zheng XX, Lott MT, et al. Familial mitochondrial encephalomyopathy (MERRF): genetic, pathophysiological, and biochemical characterization of a mitochondrial DNA disease. Cell 1988; 55: 601-610.
5. Ozawa M, Goto Y, Sakuta R, et al. The 8, 344 mutation in mitochondrial DNA: a comparison between the proportion of mutant DNA and clinico-pathologic findings. Neuromuscul Disord 1995; 5: 483-488.
6. Blakely EL, Trip SA, Swalwell H, et al. A new mitochondrial transfer RNAPro gene mutation associated with myoclonic epilepsy with ragged-red fibers and other neurological features. Arch Neurol 2009; 66: 399-402.
7. Virgilio R, Ronchi D, Bordoni A, et al. Mitochondrial DNA G8363A mutation in the tRNA Lys gene: clinical, biochemical and pathological study. J Neurol Sci 2009; 281: 85-92.
8. Hammans SR, Sweeney MG, Brockington M, et al. The mitochondrial DNA transfer RNA(Lys)A-- & G(8344) mutation and the syndrome of myoclonic epilepsy with ragged red fibers (MERRF). Relationship of clinical phenotype to proportion of mutant mitochondrial DNA. Brain 1993; 116(pt 3): 617-632.
9. Enriquez JA, Chomyn A, Attardi G. MtDNA mutation in MERRF syndrome causes defective aminoacylation of tRNA(Lys) and premature translation termination. Nat Genet 1995; 10: 47-55.
10. Yasukawa T, Suzuki T, Ishii N, et al. Defect in modification at the anticodon wobble nucleotide of mitochondrial tRNA(Lys) with the MERRF encephalomyopathy pathogenic mutation. FEBS Lett 2000; 467: 175-178.
11. James AM, Sheard PW, Wei YH, et al. Decreased ATP synthesis is phenotypically expressed during increased energy demand in fibroblasts containing mitochondrial tRNA mutations. Eur J Biochem 1999; 259: 462-469.
12. James AM, Wei YH, Pang CY, et al. Altered mitochondrial function in fibroblasts containing MELAS or MERRF mitochondrial DNA mutations. Biochem J 1996; 318(pt 2): 401-407.
13. Chomyn A, Meola G, Bresolin N, et al. In vitro genetic transfer of protein synthesis and respiration defects to mitochondrial DNA-less cells with myopathy-patient mitochondria. Mol Cell Biol 1991; 11: 2236-2244.
14. Boulet L, Karpati G, Shoubridge EA. Distribution and threshold expression of the tRNA(Lys) mutation in skeletal muscle of patients with myoclonic epilepsy and ragged-red fibers (MERRF). Am J Hum Genet 1992; 51: 1187-1200.
15. Wu SB, Ma YS, Wu YT, et al. Mitochondrial DNA mutation-elicited oxidative stress, oxidative damage, and altered gene expression in cultured cells of patients with MERRF syndrome. Mol Neurobiol 2010; 41: 256-266.
16. Quinzii C, Naini A, Salviati L, et al. A mutation in para-hydroxybenzoate-polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am J Hum Genet 2006; 78: 345-349.
17. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989; 246: 500-503.
18. Rustin P, Chretien D, Bourgeron T, et al. Biochemical and molecular investigations in respiratory chain deficiencies. Clin Chim Acta 1994; 228: 35-51.
19. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
20. Rodriguez-Hernandez A, Cordero MD, Salviati L, et al. Coenzyme Q deficiency triggers mitochondria degradation by mitophagy. Autophagy 2009; 5: 19-32.
21. Lee BY, Han JA, Im JS, et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006; 5: 187-195.
22. Sacconi S, Trevisson E, Salviati L, et al. Coenzyme Q10 is frequently reduced in muscle of patients with mitochondrial myopathy. Neuromuscul Disord 2010; 20: 44-48.
23. Vander Heiden MG, Chandel NS, Williamson EK, et al. Bcl-xL regulates the membrane potential and volume homeostasis of mitochondria. Cell 1997; 91: 627-637.
24. Scherz-Shouval R, Shvets E, Fass E, et al. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007; 26: 1749-1760.
25. Quinzii CM, Lopez LC, Naini A, et al. Human CoQ10 deficiencies. BioFactors (Oxford, England) 2008; 32: 113-118.
26. Cordero MD, De Miguel M, Moreno Fernandez AM, et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: implications in the pathogenesis of the disease. Arthritis Res Ther 2010; 12: R17.
27. Molyneux SL, Young JM, Florkowski CM, et al. Coenzyme Q10: is there a clinical role and a case for measurement? Clin Biochem Rev 2008; 29(2): 71-82.
28. Armstrong JS, Whiteman M, Rose P, et al. The coenzyme Q10 analog decylubiquinone inhibits the redox-activated mitochondrial permeability transition: role of mitcohondrial [correction mitochondrial] complex III. J Biol Chem 2003; 278: 49079-49084.
29. Cotan D, Cordero MD, Garrido-Maraver J, et al. Secondary coenzyme Q10 deficiency triggers mitochondria degradation by mitophagy in MELAS fibroblasts. FASEB J 2011; 25: 2669-2687.
30. Kim I, Rodriguez-Enriquez S, Lemasters JJ. Selective degradation of mitochondria by mitophagy. Archives of biochemistry and biophysics 2007; 462: 245-253.
31. Forte M, Bernardi P. Genetic dissection of the permeability transition pore. J Bioenerg Biomembr 2005; 37: 121-128.
32. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-176.
33. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010; 12: 119-131.